Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - sanofi pasteur

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - sanofi pasteur

Alternative Names: MCV-4; Menactra; Menactra Infant/Toddler; Menactra Toddler; Meningo ACWY; Meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine; Meningococcal polysaccharide diphtheria toxoid conjugate vaccine; SP284

Latest Information Update: 11 Apr 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Novartis Vaccines; Sanofi Pasteur
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 05 Jul 2019 Launched for Meningococcal infections (In infants, In neonates, Prevention) in India prior July 2019 (IM)
  • 02 Jul 2018 SK Chemicals divested the vaccine business portfolio to a newly formed subsidiary SK Bioscience
  • 05 Dec 2016 Sanofi completes a phase II trial for Meningococcal infections (Prevention, In infants, In children, In adolescents, In adults) in Vietnam (NCT02640404)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top